William Kelly Joins Inyx in the New Position of Vice President -- Investor Relations & Corporate Communications

NEW YORK, May 9  /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC:IYXI) (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company focused on niche drug delivery technologies and products, announced today that William Kelly has joined the company in the newly established position of Vice President -- Investor Relations & Corporate Communications.

Mr. Kelly's responsibilities include management of the company's communications with shareholders and other institutional and individual investors, key business constituencies and employees.

Jay M. Green, Executive Vice President of Inyx, Inc., said, "We are pleased that Bill has joined Inyx in this important new role at our company, since our corporate communications to key constituents today are on a global basis and growing."

"I am excited to join Inyx at this stage of its evolution into becoming a vertically integrated, specialty pharmaceutical company with significant growth opportunities because of Inyx's niche drug delivery expertise, industry positioning and strategic relationships," Mr. Kelly said.

Mr. Kelly has more than 20 years of experience in investor relations and corporate communications, which includes working with multinational companies. Prior to joining Inyx, Mr. Kelly was a consultant for more than ten years, advising a range of Nasdaq and New York Stock Exchange-listed companies, such as Taro Pharmaceuticals, Cytec Industries and BET plc as well as the accounting firm KPMG.  Earlier, he was a full-time consultant to Bristol-Myers Squibb, and he served as a Vice President with J.P. Morgan & Co.  Mr. Kelly is a graduate of Princeton University and has a MBA from Rutgers University.

About Inyx

Inyx, Inc. is a specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions.  Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services.  In addition, Inyx is developing its own proprietary products.  The company's operations are conducted through several wholly owned subsidiaries: Inyx USA, Ltd., based in Manati, Puerto Rico; Inyx Pharma Ltd. and Inyx Europe Limited, which owns and operates Ashton Pharmaceuticals Ltd., all near Manchester, England; Inyx Canada, Inc. in Toronto; and Exaeris, Inc., based in Exton, Pennsylvania.  Inyx, Inc.'s corporate offices are in New York City. For more information, please visit:  http://www.inyxgroup.com/.

Safe Harbor Statements about Inyx's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.

  For more information, please contact:
  Jay M. Green, Executive Vice President
  Inyx, Inc.
  

  Bill Kelly, VP - Investor Relations & Corporate Communications
  Inyx, Inc.
  

DATASOURCE: Inyx, Inc.



CONTACT: Jay M. Green, Executive Vice President, , or

Bill Kelly, VP - Investor Relations & Corporate Communications,

, both of Inyx, Inc.



Web site:  http://www.inyxinc.com/

Copyright